Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer
The Role of Mitochondrial Bioenergetics in Resilience in Older Adults With Gynecologic Cancer Receiving Cancer Reductive Treatment
Wake Forest University Health Sciences
30 participants
Jun 1, 2026
OBSERVATIONAL
Conditions
Summary
The purpose of this research study is to see if patients with endometrial and ovarian cancer are willing to complete physical and cognitive assessments before treatment and again after treatment has ended.
Eligibility
Inclusion Criteria5
- Ability to understand and willingness to sign an IRB-approved informed consent
- Age ≥50 years at the time of enrollment
- Newly diagnosed or suspected FIGO Stage II-IV ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype OR FIGO Stage II-IV endometrial carcinoma of any histological subtype
- Planned, standard of care treatment consisting of neoadjuvant chemotherapy, tumor reduction surgery, and adjuvant chemotherapy
- Ability to read and understand the English language
Exclusion Criteria4
- Previously treated for ovarian or endometrial cancer
- History of brain metastases, whole brain irradiation, poorly controlled psychiatric disorders defined by hospitalization within the last 3 months for psychiatric diagnoses, traumatic brain injury, cerebrovascular event, or dementia
- Currently taking anti-amyloid agents, cholinesterase inhibitors, or glutamate regulator
- Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
For participants undergoing standard of care interval cytoreductive surgery via laparotomy, a skeletal muscle biopsy from the rectus abdominis muscle (1 cm x 1 cm x 1 cm, \~300 mg) will be collected. For participants who undergo standard of care interval cytoreductive surgery with a laparoscopic approach, a skeletal muscle biopsy will be taken from either the rectus abdominis (1 cm x 1 cm x 1 cm, \~300 mg) or the psoas (1 cm x 0.5 cm x 0.5 cm, \~200 mg) muscle.
A total of approximately 60mL or 4 tablespoons of blood will be collected throughout the study
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07046936